Pharma

HIMSSCast: FDA grapples with home COVID-19 testing, moves forward with Pre-Cert Program
By HIMSS Media | 05:31 pm | March 30, 2020
The HIMSS Media team gives a recap of recent headlines surrounding the FDA, COVID-19 and new digital health software products.
MyHeritage, BGI forming COVID-19 testing lab in Israel, AstraZeneca taps BrightInsight to support its digital ecosystem and more digital health deals
By Dave Muoio | 04:50 pm | March 30, 2020
Also: Providence supporting COVID-19 patients at home with Xealth and Twistle; Lief Therapeutics incorporates DrChrono's Open API.
Q&A: A firsthand account of FDA's Pre-Cert Program
By Dave Muoio | 02:55 pm | March 27, 2020
Dr. Yuri Maricich, chief medical officer at Pear Therapeutics, speaks on his company's experience bringing a digital therapeutic product through the regulator's experimental program for health software.
FDA clears Pear's digital insomnia therapeutic through 510(k), Pre-Cert pilot pathways
By Dave Muoio | 04:53 pm | March 26, 2020
Somryst, a prescription digital therapeutic combining cognitive behavioral therapy and personalized sleep restriction, is the first software product to put the FDA's early Precertification Program framework through its paces. 
UAE entrepreneur pledges AED 5 million towards COVID-19 vaccine currently in trial
By Ahmed El Sherif | 11:33 am | March 25, 2020
Chairman of the UAE’s IBC Group is working with the UK biotech research company, Vaxbio to launch an affordable vaccine that the company hopes to launch by the summer.
HIMSS20 Digital
By HIMSS | 04:09 pm | March 24, 2020
We want to hear your COVID-19 stories
By Jonah Comstock | 03:50 pm | March 20, 2020
Digital pharmacy Genius Rx to debut this summer
By Laura Lovett | 03:17 pm | March 17, 2020
The platform will include an AI-enabled patient-engagement tool and smart pricing. 
Coronavirus forces cancellation of HIMSS20
By Healthcare IT News Staff | 02:56 pm | March 05, 2020
Full publication of pivotal trial data outlines Akili's case for FDA regulation
By Dave Muoio | 08:50 pm | February 24, 2020
The large, multi-site investigation described clear improvement in objective symptoms of pediatric attention deficit, but was a bit muddier when describing subjective measures and long-term efficacy.